[
  {
    "ts": null,
    "headline": "January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy",
    "summary": "January 2026 Dogs of the Dow update: Verizon is the only âdogcatcherâ stock.",
    "url": "https://finnhub.io/api/news?id=1660b2a2ba8c3d9e6bd7a573907b58ceded4a1a0c4d63c9ba3a114cc975bf4d3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768038721,
      "headline": "January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy",
      "id": 138055995,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1839458057/image_1839458057.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "January 2026 Dogs of the Dow update: Verizon is the only âdogcatcherâ stock.",
      "url": "https://finnhub.io/api/news?id=1660b2a2ba8c3d9e6bd7a573907b58ceded4a1a0c4d63c9ba3a114cc975bf4d3"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain?",
    "summary": "If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through what the numbers are really saying about the stock. Over the last year Amgen has returned 28.4%, with a 3.4% gain over the past 30 days, while the year-to-date return and 7-day move both sit at 0.5% declines, which may have shifted how some investors think about its potential and risk. Recent headlines around Amgen have focused on its position as a large biotech player,...",
    "url": "https://finnhub.io/api/news?id=ba46b45200ece2f690610f0bbc90ef2dac1641197479c7219d344cb5c8fea924",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768010991,
      "headline": "Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain?",
      "id": 138052464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through what the numbers are really saying about the stock. Over the last year Amgen has returned 28.4%, with a 3.4% gain over the past 30 days, while the year-to-date return and 7-day move both sit at 0.5% declines, which may have shifted how some investors think about its potential and risk. Recent headlines around Amgen have focused on its position as a large biotech player,...",
      "url": "https://finnhub.io/api/news?id=ba46b45200ece2f690610f0bbc90ef2dac1641197479c7219d344cb5c8fea924"
    }
  }
]